Immatics US, Inc.
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ACTengine® IMA203 Combined With mRNA-4203 (NCT06946225) | Immatics US, Inc. | 2025-07-25 |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (NCT06743126) | Immatics US, Inc. | 2025-01-14 |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (NCT03686124) | Immatics US, Inc. | 2019-05-14 |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 (NCT03441100) | Immatics US, Inc. | 2019-05-02 |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling (NCT03760952) | Immatics US, Inc. | 2019-02-26 |
| TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (NCT03247309) | Immatics US, Inc. | 2018-12-19 |
Track Immatics US, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.